PEMBROLIZUMAB
Clinical trials for PEMBROLIZUMAB explained in plain language.
Never miss a new study
Get alerted when new PEMBROLIZUMAB trials appear
Sign up with your email to follow new studies for PEMBROLIZUMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple-drug attack aims to shrink returning ovarian tumors
Disease control Recruiting nowThis study tests whether a combination of three drugs—weekly paclitaxel (or nab-paclitaxel), pembrolizumab, and mirabegron—can shrink tumors in adults whose ovarian cancer has returned. About 20 participants will receive the drugs and visit the clinic every two months for checkup…
Matched conditions: PEMBROLIZUMAB
Phase: PHASE2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated May 26, 2026 08:58 UTC
-
New drug combo aims to shrink rare sarcomas
Disease control Recruiting nowThis study tests whether two drugs, zanzalintinib and pembrolizumab, can help control advanced or metastatic soft-tissue sarcoma. About 20 adults with specific sarcoma types will receive the combination. The main goal is to check safety and side effects.
Matched conditions: PEMBROLIZUMAB
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC